Trial Profile
Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520 by Advanced Tumor Subjects
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Rulonilimab (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Shandong New Time Pharmaceutical Co LTD
- 24 Mar 2020 Planned End Date changed from 8 Oct 2021 to 8 Oct 2022.
- 24 Mar 2020 Planned primary completion date changed from 8 Feb 2020 to 8 Feb 2021.
- 15 Apr 2019 Status changed from not yet recruiting to recruiting.